A new treatment for moderate to severe eczema is showing real promise. Telikibart (GR1802, Genrix), a fully human monoclonal antibody that targets interleukin-4 and -13 — key drivers of the type 2 immune response behind atopic dermatitis (AD) — delivered impressive results in a 52-week, randomized, placebo-controlled phase 3 trial presented at the European Academy of Dermatology and Venereology Congress.

The trial enrolled 450 adults with moderate to severe AD. Participants received either telikibart or placebo during a 16-week induction period, after which placebo patients were switched to telikibart for the remaining 36 weeks.

By the Numbers:

• 69.6% of telikibart patients achieved EASI 75 (significant skin clearance) by week 16 vs. 22.5% on placebo
• 33.1% vs. 6.6% achieved an IGA score of 0 or 1 (clear/almost clear skin) by week 16
• By week 52, ~95% of patients across both groups achieved EASI 75
• ~76% of participants saw meaningful itch reduction by week 52

Why it matters: With IL-4 receptor alpha inhibitors currently used in only 22% of AD patients in China, telikibart's strong efficacy — including in patients previously treated with other biologics — and favorable safety profile (notably low conjunctivitis rates) could expand treatment options for the millions living with this chronic, debilitating skin condition.